Isothermal HCV Nucleic Acid Detection Kit
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting Hepatitis C virus (HCV) nucleic acid are not suitable for hard-to-reach populations and low resource settings, as they are laboratory-based, time-consuming, and costly, and antibody-based tests can only detect infection 6-12 weeks post-infection, necessitating a need for rapid point-of-care (POC) tests that can detect HCV as soon as possible after infection.
Innovation Solution
A method using isothermal nucleic acid amplification with forward and reverse primers that hybridize specifically to conserved regions of the HCV core nucleic acid sequence, allowing for rapid detection of HCV nucleic acid in a sample, including genotypes 1-6, without the need for laboratory facilities or thermal cyclers, using a kit that includes primers, probes, and enzymes for isothermal amplification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If laboratory-based nucleic acid testing methods are used, then detection accuracy is improved, but device complexity and cost increase, making them unsuitable for resource-limited settings
Solution Approach 1:
The patent replaces complex laboratory-based mechanical and thermal systems (thermal cyclers, centrifuges, automated liquid handlers) with a simplified isothermal amplification system that operates at constant temperature using enzymatic reactions. This substitution maintains detection accuracy while dramatically reducing device complexity and enabling portability for resource-limited settings.
Solution Approach 2:
The patent employs disposable microfluidic cartridges or reaction strips that integrate all necessary reagents, primers, and detection components in a single-use format. This eliminates the need for expensive, complex laboratory equipment while maintaining detection accuracy, as each disposable unit is pre-configured for isothermal amplification and detection of HCV nucleic acid.
2Loss of time
If antibody-based tests are used, then cost is reduced, but detection time is delayed until 6-12 weeks post-infection
Solution Approach 1:
The patent targets conserved regions in the HCV core nucleic acid sequence that are present early in infection. By designing primers and probes that specifically bind to these conserved regions, the system enables detection of HCV RNA as soon as it becomes detectable in the patient's sample, eliminating the 6-12 week delay inherent in antibody-based tests while maintaining manufacturing simplicity.
Solution Approach 2:
The patent changes the detection parameter from antibody presence (immunological detection) to nucleic acid amplification (molecular detection). This parameter change allows detection of the viral genome itself rather than the host's immune response, enabling much earlier detection (within 1-2 weeks of infection) while using simple isothermal amplification chemistry that is easy to manufacture and deploy.
3Device complexity
If isothermal amplification is used, then device complexity is reduced, but measurement precision may be compromised
Solution Approach 1:
The patent applies local quality by designing highly specific primers and probes that target unique conserved regions within the HCV core sequence. This localized specificity ensures that even though the amplification process is simpler (isothermal), the detection remains highly accurate and genotype-specific, distinguishing between different HCV genotypes 1-6 without cross-reactivity.
Solution Approach 2:
The patent introduces carefully designed oligonucleotide primers and probes as intermediaries that mediate between the simple isothermal amplification process and the specific detection of HCV nucleic acid. These intermediaries contain sequence-specific binding sites that ensure high measurement precision while the isothermal conditions maintain low device complexity, allowing accurate differentiation of HCV genotypes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables rapid detection of HCV infection within 1-2 weeks of infection, facilitating timely treatment and monitoring, and can identify the responsible genotype, making it suitable for resource-limited settings and improving early detection capabilities.
Implementation Method 1
each nucleic acid amplification primer hybridises specifically to HCV core nucleic acid sequence, or the complement thereof, that is conserved between at least HCV genotypes 1-6
Implementation Method 2
amplifying nucleic acid of the sample, or amplifying nucleic acid derived from nucleic acid of the sample, by an isothermal amplification reaction
Data Source
AI summary
Methods for detecting Hepatitis C virus (HCV) nucleic acid are described. The methods are useful for point-of-care (POC) testing, and provide rapid tests able to detect several different HCV genotypes. Kits, primers, probes, sets of primers, sets of 5 oligonucleotides, and oligonucleotides, and their use in the methods, are also described.